Therapy of respiratory tract diseases using basic fibroblast gro

Details Therapy of respiratory tract diseases using basic fibroblast gro Therapy of respiratory tract diseases using basic fibroblast gro

1993-10-22

1996-05-07

Allen, Marianne P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530399, 435 691, 435 694, 514826, A61K 3818, C12N 1500

Patent

active

055146520

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to a preparation the therapy of respiratory tract diseases, used for the therapy of allergic and anallergic respiratory tract diseases or respiratory tract or bronchial tube impairments caused by the inhalation of respiratory tract impairing substances such as acids.


TECHNICAL BACKGROUND

For the therapy of respiratory tract diseases such as allergic or anallengic asthma or chronic or acute bronchitis, a xanthine derivative, a .beta.sympathetic nerve acceptor stimulating preparation and an anticholine preparation are used as a bronchial tube dilating preparation. These preparations ape used in various forms such as a tablet, a powder, granules, a suppository, syrup, an intravenous solution, a hypodermic solution, an intramuscular preparation and an inhalant. The preparation form is selected from these depending upon the disease graveness and age of a patient.
Further, for the therapy of the above diseases at an intermediate or higher graveness level in particular, a steroidal drug having anti-inflammatory activity is used. This drug is known to have not only anti-inflammatory activity but also a therapeutical effect on the incompetent state of a .beta.acceptor. This drug is mainly intravenously administered at present, while it is recently being emphasized that this drug has efficacy when administered by inhalation.
An anti-allergic drug is used as a drug for preventing respiratory tract diseases such as allergic asthma or chronic or acute bronchitis. This drug exhibits its effect by inhibiting the antagonistic activity to mediators such as histamine and leucotriene and the release of the mediators from mast cells.
Preparations according to Chinese medicine such as Ephedrea herba, Bupleuri radix and a fluid therapy agent are recently used alone or in combination for the therapy of the above diseases. Further, there are used specific therapies using allergenic extracts and a nonspecific alterative treatment agent using a gold preparation, bacterial vaccine and histamine-added .gamma.-globulin although the mechanism of the latter for producing an effect has not yet been made clear.
Respiratory tract diseases caused by a respiratory system disease are therapeutically treated depending upon the diseases. For example, in infectious diseases, an antibiotic is administered in addition to the above drugs.
In respiratory tract diseases (injury) caused by the inhalation of an acid or an organic solvent or by the inhalation of hot air, not only autotherapy is expected but also an anti-inflammatory preparation such as a steroidal drug or an antibiotic against a possible infectious disease is used.
A basic fibroblast proliferation factor (also called a basic fibroblast growth factor, to be referred to as "bFGF" hereinafter) is a peptidyl cell growth factor which has been recognized to be present in the pituitary, brain, retina, corpus luteum, adrenal, kidney, placenta, prostate, thymus, chondrosarcoma and macrophage of a human being and other specific mammals (Cell Growth Factor, Part II, compiled by Japanese Tissue Culture Society, Asakura Publishing Co.). In the beginning, it has been found that bFGF exhibits high proliferation activity in a fibroblast such as BALB/c3T3 (D. Gospondarowicz: Nature 249: 123, 1974), and it was named such due to this activity. Then, it has been also found that it promotes the proliferation of almost all cells from amesoderm, particularly an endothelial cell (D. Gospondarowicz: National Cancer Institute Monograph 48: 109, 1978) and also promotes the proliferation of satellite cells of skeletal muscle (R. E. Allen: Exp. Cell Res. 152: 154, 1984).
Further, the clinical application of bFGF to various diseases is being studied recently. For example, bFGF is clinically applied to the therapy of wound, and bFGF is also clinically applied to the restoration of a blood vessel using its vascularization activity.
Moreover, a fibroblast-derived epithelial growth factor has been recently found, and it may be therefore inferred that the production of th

REFERENCES:
patent: 4956455 (1990-09-01), Esch et al.
patent: 4994559 (1991-02-01), Moscatelli et al.
patent: 5006343 (1991-04-01), Benson et al.
Albes et al The Annals of Thoraeic Surgery, 57(2):444-449 (1994).
Basilico et al Adv. Cancer Res 59:115-165 (1992).
Bejin et al Chest 95(4):842-849 (1989).
Cormier et al Chest 104(4):1038-1042 (1993).
Henke et al America J. of Pathology 143(4):1189-1199 (1993).
Lemaire et al Am. Review of Resp. Diseases 134(4):653-658 (1986).
Thornton et al. Clin Exp Immunol 90:447-452 (1992).

Affiliated with

Also associated with

Rating

Therapy of respiratory tract diseases using basic fibroblast gro does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy of respiratory tract diseases using basic fibroblast gro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy of respiratory tract diseases using basic fibroblast gro will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1227255